- Home
- ELVN vs FLGT Comparison
ELVN vs FLGT Comparison
Compare ELVN & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELVN | FLGT |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 867.4M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ELVN | FLGT |
|---|---|---|
| Price | $28.49 | $23.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $41.00 | $28.33 |
| AVG Volume (30 Days) | ★ 683.8K | 166.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.97 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $18,730,000.00 |
| Revenue This Year | N/A | $16.84 |
| Revenue Next Year | N/A | $9.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.30 | $14.57 |
| 52 Week High | $30.22 | $31.04 |
Technical Indicators
Market Signals| Indicator | ELVN | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 62.37 | 26.38 |
| Support Level | $18.41 | $21.97 |
| Resistance Level | $29.63 | $23.70 |
| Average True Range (ATR) | 1.51 | 0.76 |
| MACD | -0.25 | -0.03 |
| Stochastic Oscillator | 64.74 | 11.84 |
Price Performance
Historical ComparisonAbout ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.